
Sign up to save your podcasts
Or


In the relentlessly evolving landscape of drug discovery, modern technologies and groundbreaking methods are going beyond animal testing to ensure a more human-centric, efficient, and improved approach in terms of reliability. It's a journey that promises a more efficient future for pharmaceutical companies and, ultimately, patients worldwide.
Dive into the details with industry leader Professor Thomas Hartung, shedding light on how policy changes and innovative technologies are setting the stage for the future.
What You'll Learn
00:15 β Cutting-Edge Advances in Non-Animal Testing
07:50 β Regulatory Shifts with the FDA Modernization Act
15:30 β The Role of AI in Drug Discovery
24:10 β Integrating New Approaches into Current Practices
Main Points of Conversation:
In a time when the complexities of drug development demand rapid, accurate solutions, the adoption of alternative methodologies is crucial. As regulatory bodies worldwide signal a shift away from animal testing, the opportunities for innovative technologies to provide human-relevant data are immense. Executives and decision-makers must understand these transformations to maintain competitive advantages and drive industry standards forward.
By π₯Crown BioscienceIn the relentlessly evolving landscape of drug discovery, modern technologies and groundbreaking methods are going beyond animal testing to ensure a more human-centric, efficient, and improved approach in terms of reliability. It's a journey that promises a more efficient future for pharmaceutical companies and, ultimately, patients worldwide.
Dive into the details with industry leader Professor Thomas Hartung, shedding light on how policy changes and innovative technologies are setting the stage for the future.
What You'll Learn
00:15 β Cutting-Edge Advances in Non-Animal Testing
07:50 β Regulatory Shifts with the FDA Modernization Act
15:30 β The Role of AI in Drug Discovery
24:10 β Integrating New Approaches into Current Practices
Main Points of Conversation:
In a time when the complexities of drug development demand rapid, accurate solutions, the adoption of alternative methodologies is crucial. As regulatory bodies worldwide signal a shift away from animal testing, the opportunities for innovative technologies to provide human-relevant data are immense. Executives and decision-makers must understand these transformations to maintain competitive advantages and drive industry standards forward.